Diabetes Metab J.  2021 Nov;45(6):972-973. 10.4093/dmj.2021.0315.

Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707)

• Han E
• Kim HS

• KMID: 2522739
• DOI: http://doi.org/10.4093/dmj.2021.0315

Reference

1. Han E, Kim MK, Jang BK, Kim HS. Albuminuria is associated with steatosis burden in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Diabetes Metab J. 2021; 45:698–707.

2. European Association for the Study of the Liver; Clinical Practice Guideline Panel; EASL Governing Board representative. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis: 2021 update. J Hepatol. 2021; 75:659–89.

3. Ando Y, Jou JH. Nonalcoholic fatty liver disease and recent guideline updates. Clin Liver Dis (Hoboken). 2021; 17:23–8.

4. Hur KY, Kim MK, Ko SH, Han M, Lee DW, Kwon HS, et al. Metformin treatment for patients with diabetes and chronic kidney disease: a Korean Diabetes Association and Korean Society of Nephrology Consensus Statement. Diabetes Metab J. 2020; 44:3–10.

5. Liu C, Chen H, Liu C, Fu C, Zhang H, Yang H, et al. Combined application of eGFR and albuminuria for the precise diagnosis of stage 2 and 3a CKD in the elderly. J Nephrol. 2014; 27:289–97.

6. Shardlow A, McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW. Chronic kidney disease in primary care: outcomes after five years in a prospective cohort study. PLoS Med. 2016; 13:e1002128.

7. Yeung MW, Wong GL, Choi KC, Luk AO, Kwok R, Shu SS, et al. Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. J Hepatol. 2018; 68:147–56.